Nefrovita - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 215,858 | 479,893 | 539,163 | 561,685 | 565,150 | 520,242 | 575,864 | 623,616 |
| Profit before tax | -102,290 | 81,150 | 159,487 | 131,323 | 71,843 | 43,053 | 91,241 | 106,085 |
| Net profit | -102,290 | 81,150 | 159,487 | 131,323 | 71,843 | 43,030 | 91,241 | 100,617 |
| Equity | -126,841 | -45,691 | 113,796 | 245,118 | 316,961 | 209,991 | 161,232 | 183,001 |
| Liabilities | 331,645 | 294,560 | 207,042 | 43,068 | 68,896 | 67,941 | 84,854 | 100,135 |
| Non-current assets | 136,841 | 115,330 | 160,973 | 108,565 | 88,190 | 72,789 | 56,095 | 47,247 |
| Current assets | 67,598 | 133,287 | 159,721 | 179,166 | 296,623 | 204,113 | 188,766 | 235,667 |
| Total assets | 204,439 | 248,617 | 320,694 | 287,731 | 384,813 | 276,902 | 244,861 | 282,914 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 78,083 | 81,740 | 69,061 |
| Social insurance contributions | - | - | - | - | - | 61,124 | 70,546 | 74,666 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | +122.3% | +12.4% | +4.2% | +0.6% | -7.9% | +10.7% | +8.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -50.0% | 32.6% | 49.7% | 45.6% | 18.7% | 15.5% | 37.3% | 35.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | 140.2% | 53.6% | 22.7% | 20.5% | 56.6% | 55.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -47.4% | 16.9% | 29.6% | 23.4% | 12.7% | 8.3% | 15.8% | 16.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -47.4% | 16.9% | 29.6% | 23.4% | 12.7% | 8.3% | 15.8% | 17.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | 1.8 | 0.2 | 0.2 | 0.3 | 0.5 | 0.5 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 26,431 | 36,447 | 41,474 | 40,120 | 37,469 | 28,377 | 30,176 | 30,544 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Nefrovita - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-05-17 | 2026-05-20 | 0.37 |
| 2026-05-03 | 2026-05-11 | 0.38 |
| 2026-04-23 | 2026-04-29 | 0.38 |
| 2026-02-24 | 2026-02-24 | 222.85 |
| 2026-02-18 | 2026-02-23 | 233.87 |
| 2025-11-18 | 2025-11-18 | 61.82 |
Nefrovita - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-01-03 | 2026-01-05 | 5906.51 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Nefrovita, UAB (code 304347282) is a private limited liability company operating in medical specialists activities. In 2025, the company generated revenue of €623.6K and net profit of €100.6K, with a profit margin of 16.1%. Revenue increased by 8.3% year on year and by 19.9% over two years, showing a steady upward trend. Profit also improved materially across the period, rising from €43.0K in 2023 to €91.2K in 2024 and €100.6K in 2025. The balance sheet remained solid in 2025, with total assets of €282.9K, equity of €183.0K and liabilities of €100.1K. Key ratios point to strong profitability and efficient use of assets, including ROE of 55.0%, ROA of 35.6%, debt-to-equity of 0.55 and asset turnover of 2.20x. Revenue per employee was €31.2K and profit per employee €5.0K, indicating moderate productivity in the latest year.